MedDataX Logo

Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers

NCT ID: NCT01655511

Last Updated: 2012-09-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study in healthy male and female volunteers will investigate the safety and tolerability of three increasing oral doses of tafamidis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)

NCT03662191

Healthy Volunteers
COMPLETED PHASE1

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

NCT01731327

Healthy
COMPLETED PHASE1

A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples

NCT02189330

Healthy Volunteers
COMPLETED PHASE1

Pharmacokinetics And Safety Study Of Two CP-690,550 Controlled Release Formulation Following Single Dose In Healthy Volunteers

NCT01185184

Healthy
COMPLETED PHASE1

A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants

NCT05482308

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

TTR Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Period 1

240 mg tafamidis arm

Group Type EXPERIMENTAL

Tafamidis

Intervention Type DRUG

240 mg, solution, single dose

Period 2

480 mg arm

Group Type EXPERIMENTAL

Tafamidis

Intervention Type DRUG

480 mg, solution, single dose

Period 3

TBD dose

Group Type EXPERIMENTAL

Tafamidis

Intervention Type DRUG

TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tafamidis

240 mg, solution, single dose

Intervention Type DRUG

Tafamidis

480 mg, solution, single dose

Intervention Type DRUG

Tafamidis

TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, males or females, 21 to 55 years old.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.

Exclusion Criteria

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Condition affecting drug absorption. Blood pressure or ECG abnormalities. Recent treatment with an investigational, prescription, or non-prescription drug
Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Singapore, Singapore, Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3461040&StudyName=Safety%20And%20Pharmacokinetic%20Assessment%20Of%20Orally%20Administered%20Tafamidis%20In%20Healthy%20Volunteers

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B3461040

Identifier Type: -

Identifier Source: secondary_id

B3461040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacokinetics of Faldaprevir of Soft Capsule
NCT01821937 COMPLETED PHASE1
A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants
NCT05051553 COMPLETED PHASE1
A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults
NCT06273839 COMPLETED PHASE1
Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions
NCT02561741 COMPLETED PHASE1
A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers
NCT01499004 COMPLETED PHASE1
A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function
NCT01222455 COMPLETED PHASE1
A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers
NCT01901159 COMPLETED PHASE1
A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects
NCT01260155 COMPLETED PHASE1
A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants
NCT04696393 COMPLETED PHASE1
A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
NCT04121078 COMPLETED PHASE1
PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations
NCT03112148 COMPLETED PHASE1
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
NCT03465059 COMPLETED PHASE1
A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects
NCT05103878 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers
NCT02215759 COMPLETED PHASE1
Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers
NCT02215018 COMPLETED PHASE1
Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment
NCT03114540 COMPLETED PHASE1
To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers
NCT02093819 COMPLETED PHASE1
A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
NCT03280173 COMPLETED PHASE1
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
NCT05661344 COMPLETED PHASE1
Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions
NCT02561650 COMPLETED PHASE1
Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers
NCT02293148 COMPLETED PHASE1
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy Volunteers
NCT05155995 COMPLETED PHASE1
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
NCT05481411 COMPLETED PHASE1
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
NCT01208155 COMPLETED PHASE1
Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers
NCT05995119 COMPLETED EARLY_PHASE1